SELECTHERA

About 4HF Biotec

4HF Biotec is a private, preclinical-stage biotech leveraging a unique AI-driven in silico platform, the 4HF CancerDataMiner™, to discover and develop novel small molecule drug conjugates (SMDCs) for oncology. The company operates a hybrid business model, advancing its own pipeline while offering in silico research services to industry partners. Its lead project, SELECTHERA, is a collaboration with the German Cancer Research Center (DKFZ/DKTK) focused on developing tumor-selective toxins and radioligands for prostate and lung cancer.

Therapeutic Areas